Calmodulin antagonists promote TRA-8 therapy of resistant pancreatic cancer

Pancreatic cancer is highly malignant with limited therapy and a poor prognosis. TRAIL-activating therapy has been promising, however, clinical trials have shown resistance and limited responses of pancreatic cancers. We investigated the effects of calmodulin(CaM) antagonists, trifluoperazine(TFP) a...

Descripción completa

Detalles Bibliográficos
Autores principales: Yuan, Kaiyu, Yong, Sun, Xu, Fei, Zhou, Tong, McDonald, Jay M, Chen, Yabing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2015
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4694833/
https://www.ncbi.nlm.nih.gov/pubmed/26320171

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4694833/
https://www.ncbi.nlm.nih.gov/pubmed/26320171

Ejemplares similares